07:00 , Jul 25, 2016 |  BC Week In Review  |  Company News

Bind Therapeutics, Pfizer deal

Bind accepted a “stalking horse” bid from Pfizer to acquire substantially all of the biotech’s assets for $20 million in cash. Subject to bankruptcy court approval, and if Pfizer’s bid remains the highest and best...
07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Shedding red

Steve Edelson, Senior Editor   Brexit nearly wiped out what looked to be a rebound quarter for biotech. Only two market cap segments finished in positive territory, and smaller companies continued to get pounded. Big caps...
07:00 , Apr 18, 2016 |  BC Week In Review  |  Company News

Bind Therapeutics cancer, drug delivery news

Bind will reduce headcount by about 37 (38%) to 61 and restructure to reduce operating expenses. In December, the company said it will shift its focus from using its Accurins platform technology for improvement of...
07:00 , Apr 18, 2016 |  BC Week In Review  |  Clinical News

BIND-014: Phase II halted

Bind halted further enrollment in the open-label, international Phase II iNSITE 2 trial evaluating IV BIND-014 after the product led an ORR of 10% in the SCCHN cohort (n=20) and 0% in the cervical cancer...
07:00 , Apr 18, 2016 |  BC Week In Review  |  Clinical News

BIND-014: Updated Phase II data

Data from 40 patients with NSCLC who progressed after a previous platinum-containing chemotherapy regimen in intent-to-treat (ITT) population of the squamous histology cohort of the open-label, international Phase II iNSITE 1 trial showed that 60...
07:00 , Apr 11, 2016 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changesCompanyBankAnalystCoverageOpinionWk chg4/8 clsBind Therapeutics Inc. (NASDAQ:BIND)CowenEric SchmidtDowngradeMarket perform (from outperform)-30%$1.57 Michael KingDowngradeMarket perform (from market outperform)Schmidt downgraded after Bind reported mixed results from two Phase II trials of BIND-014....
08:00 , Feb 8, 2016 |  BC Week In Review  |  Clinical News

BIND-014: Phase II ongoing

Bind discontinued enrollment in the cholangiocarcinoma and bladder cancer cohorts of the open-label, international Phase II iNSITE 2 trial evaluating IV BIND-014 due to lower than anticipated enrollment. The study also completed enrollment of at...
08:00 , Feb 8, 2016 |  BC Week In Review  |  Clinical News

BIND-014: Completed Phase II enrollment

Bind completed enrollment of about 40 patients in the squamous histology cohort of the open-label, international Phase II iNSITE 1 trial evaluating 60 mg/kg IV BIND-014 every 3 weeks. In December, the company said it...
08:00 , Dec 21, 2015 |  BC Week In Review  |  Clinical News

BIND-014: Phase II data

Bind said that based on a planned interim analysis it will advance the squamous histology NSCLC cohort but not the K-Ras ( KRAS)-mutation NSCLC cohort into the second stage of the open-label, international Phase...
07:00 , Sep 21, 2015 |  BC Week In Review  |  Clinical News

BIND-014: Phase II started

Bind began the open-label, international Phase II iNSITE 2 trial to evaluate IV BIND-014 in up to 160 patients with cholangiocarcinoma, advanced cervical cancer, advanced bladder cancer or advanced SCCHN. Bind Therapeutics Inc. (NASDAQ:BIND), Cambridge,...